Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
71 Results Found
AHA submits comments on draft drug shortage legislation to Senate Finance Committee leaders
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide Medicare incentive payments to hospitals.
AHA Comments on Senate Finance Committee’s Drug Shortage Draft Legislation
AHA thanks the Senate Committee on Finance for the opportunity to comment on its draft legislation, the “Drug Shortage Prevention and Mitigation Act.”
Drug Prices and Shortages Increase Hospitals’ Costs and Jeopardize Patient Access to Care Infographic
Drug companies continue to introduce new drugs at record prices. The median annual list price for new drugs in 2023 was $300,000, an increase of 35% over the previous year.
Drug Prices and Shortages Jeopardize Patient Access to Quality Hospital Care
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient o
ASHP reports record high number of drug shortages
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previ
HHS proposes policies to prevent drug shortages
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior.
AHA recommends legislative action to address chronic drug shortages
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to diversify manufacturing sites and sources for critical pharmaceutical ingredients; support an increase in end-user and supply chain inventories for critical medications; develop a rating system for drug maker quality management processes; identify essential drugs needing more domestic manufacturing capacity; and require drug makers to disclose where their products are made and when demand for essential drugs spikes.
AHA Comments before House Committee on Ways and Means on "Examining Chronic Drug Shortages in the United States"
AHA comments to the House Committee on Ways and Means regarding the important topic of drug shortages in the United States.
AHA-supported drug shortages bill introduced in House
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation that would require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain.
AHA comments on drug shortages for Senate hearing on policy solutions
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its support for multiple bills in the Senate to address drug shortages and shore up the nation’s fragile pharmaceutical supply chain.